Healio nAMD, DME, and MacTel: Innovative Delivery Systems
Innovative drug classes and advanced delivery systems are transforming the therapeutic landscape for degenerative retinal diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular telangiectasia (MacTel).
In this CE activity, experts in the field report the latest clinical data on these novel therapies and delivery systems and discuss the role these agents will play in the ever-evolving management of nAMD, DME, and MacTel.
Key Features
Innovative drug classes and advanced delivery systems are transforming the therapeutic landscape for degenerative retinal diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular telangiectasia (MacTel). While anti-vascular endothelial growth factor (VEGF) therapies have revolutionized care for these conditions, the associated frequent injection protocols often result in substantial patient discomfort and noncompliance. Recently, multiple delivery systems have been designed to enhance therapeutic durability through sustained release or prolonged drug delivery, reducing the burden on patients’ quality of life. For example, tyrosine kinase inhibitors (TKIs), administered in suspension or within a bioerodible insert, have demonstrated positive efficacy outcomes with significantly extended treatment intervals for patients with nAMD and DME. Additionally, in March 2025, an encapsulated cell therapy became the first FDA-approved treatment for MacTel type 2. In this CE activity, experts in the field report the latest clinical data on these novel therapies and delivery systems and discuss the role these agents will play in the ever-evolving management of nAMD, DME, and MacTel.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
1. Summarize the most recent clinical data on TKIs and their role in novel delivery systems for the management of patients with retinal diseases.
2. Evaluate the latest clinical data regarding novel delivery systems for the management of patients with MacTel.
Target Audience
The intended audience for this activity includes retina specialists and ophthalmologists involved in the management of patients with nAMD, DME, and MacTel.
Additional credit info
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.